The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of combination therapy with S-1 and cetuximab in patients with KRAS wild-type unresectable colorectal cancer who had previously received irinotecan, oxaliplatin, and fluoropyrimidines (KSCC0901).
Kazuma Kobayashi
No relevant relationships to disclose
Yasunori Emi
No relevant relationships to disclose
Yoshihiro Kakeji
No relevant relationships to disclose
Takao Takahashi
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Yoshito Akagi
No relevant relationships to disclose
Akihito Tsuji
No relevant relationships to disclose
Yasuhiro Kodera
Research Funding - Taiho Pharmaceutical
Kazuhiro Yoshida
Research Funding - Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical
Hideo Baba
Research Funding - Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical
Mitsuo Shimada
Research Funding - Taiho Pharmaceutical (I)
Yutaka Ogata
No relevant relationships to disclose
Mototsugu Shimokawa
No relevant relationships to disclose
Shoji Tokunaga
No relevant relationships to disclose
Shoji Natsugoe
No relevant relationships to disclose
Yoshihiko Maehara
Research Funding - Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical